ESTROGEL
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ESTROGEL (ESTROGEL).
Estradiol is a steroid hormone that binds to estrogen receptors (ERα and ERβ), activating gene transcription and non-genomic signaling pathways, leading to proliferation and differentiation of target tissues including breast, endometrium, and bone.
| Metabolism | Primarily hepatic metabolism via cytochrome P450 isoenzymes (CYP3A4, CYP1A2, CYP2C9, CYP2C19, CYP2D6) and conjugation (glucuronidation, sulfation). Enterohepatic recirculation occurs. Metabolites include estrone, estriol, and conjugated estrogens. |
| Excretion | Estradiol and its metabolites are primarily excreted in urine (≈90%) after conjugation (glucuronide and sulfate) in the liver, with the remainder eliminated in feces (≈10%) via bile. Less than 5% is excreted as unchanged parent drug. |
| Half-life | The terminal elimination half-life of estradiol after transdermal administration is approximately 10–15 hours, supporting once-daily or twice-weekly dosing regimens. The half-life of estrone (major metabolite) is longer (12–20 hours), contributing to sustained estrogenic effects. |
| Protein binding | Approximately 98–99% of circulating estradiol is bound to serum proteins: ≈60% bound to sex hormone-binding globulin (SHBG) and ≈38% bound to albumin. Free estradiol fraction is 1–2%. |
| Volume of Distribution | The apparent volume of distribution (Vd) for estradiol after transdermal administration is approximately 1–2 L/kg, indicating extensive distribution into tissues, including adipose tissue and reproductive organs. |
| Bioavailability | Bioavailability of estradiol via transdermal gel route is approximately 10–20% (fraction of applied dose that reaches systemic circulation). The remainder is lost to metabolism in the skin and evaporation. Oral bioavailability is <5% due to extensive first-pass hepatic metabolism. |
| Onset of Action | Onset of clinical effect (e.g., relief of vasomotor symptoms) typically occurs within 2–4 weeks of regular once-daily application. Peak serum estradiol levels are reached within 2–8 hours after application. |
| Duration of Action | Duration of clinical effect for symptom relief is sustained over 24 hours with daily administration due to continuous transdermal delivery. Effects on bone mineral density require prolonged therapy (>6 months). |
| Molecular Weight | 272.38 |
1.25 g (equivalent to 0.75 mg estradiol) applied once daily to upper arm or inner thigh; dose may be increased to 2.5 g (1.5 mg) depending on response.
| Dosage form | GEL, METERED |
| Renal impairment | No dosage adjustment required for mild to moderate renal impairment; not studied in severe impairment (CrCl <30 mL/min). Use with caution. |
| Liver impairment | Contraindicated in severe hepatic disease (Child-Pugh class C). For mild to moderate impairment (Child-Pugh A or B), no specific dose adjustment; monitor liver function. |
| Pediatric use | Not approved for use in pediatric patients. |
| Geriatric use | Use the lowest effective dose for the shortest duration. Limited data in women >65 years; consider increased risk of dementia and cardiovascular events. No specific dose adjustment. |
| 1st trimester | Estradiol is contraindicated in pregnancy. Use during the first trimester may cause fetal harm. Animal studies have shown adverse effects, and there are no adequate human studies. |
| 2nd trimester | Contraindicated in pregnancy. Estrogens should not be used during the second trimester due to potential risks to the fetus. |
| 3rd trimester | Contraindicated in pregnancy. Use during the third trimester is associated with an increased risk of fetal genital tract abnormalities and other adverse outcomes. |
Clinical note
Comprehensive clinical and safety monograph for ESTROGEL (ESTROGEL).
| Placental transfer | Estradiol crosses the placenta readily. Transplacental transfer has been documented in human studies, achieving significant fetal serum levels. |
| Breastfeeding | Estradiol is excreted in human milk. It may reduce milk production and quality. Use while breastfeeding is not recommended. If used, monitor the infant for signs of estrogen exposure, such as breast enlargement or vaginal bleeding. |
■ FDA Black Box Warning
Estrogens should not be used to prevent cardiovascular disease or dementia. Estrogen-alone therapy increases the risk of endometrial cancer; use with progestin in women with intact uterus. Increased risk of stroke and deep vein thrombosis (DVT) in postmenopausal women. Estrogen plus progestin therapy increases risk of pulmonary embolism, DVT, stroke, and myocardial infarction. Increased risk of breast cancer with estrogen plus progestin. Estrogens may increase risk of ovarian cancer.
| Serious Effects |
Known or suspected pregnancyUndiagnosed abnormal genital bleedingKnown or suspected breast cancerActive thromboembolic disorders or history of suchKnown or suspected estrogen-dependent neoplasia
| Precautions | Cardiovascular disorders (stroke, MI, thromboembolism), Malignant neoplasms (endometrial, breast, ovarian), Gallbladder disease, Hypercalcemia in patients with bone metastases, Fluid retention with cardiac or renal impairment, Elevated blood pressure, Hypertriglyceridemia, Impaired liver function, Hypothyroidism requiring increased thyroid replacement, Exacerbation of asthma, diabetes mellitus, epilepsy, migraine, porphyria, SLE, and hepatic hemangiomas |
| Food/Dietary |
Loading safety data…
| Lactation Rating | L4 (Possibly Hazardous) |
| Teratogenic Risk | Estradiol is contraindicated in pregnancy. First trimester: Increased risk of congenital anomalies including cardiovascular defects and neural tube defects from exogenous estrogens. Second and third trimester: Potential for feminization of male fetus, urogenital abnormalities, and long-term reproductive tract effects. Avoid use in pregnant women. |
| Fetal Monitoring | If inadvertent exposure occurs during pregnancy, monitor fetal development with ultrasound for anomalies. Maternal monitoring includes blood pressure, signs of thromboembolism, and hepatic function. No routine fetal monitoring is indicated unless exposure is prolonged. |
| Fertility Effects | Estradiol may inhibit ovulation and fertility when used as contraception. After discontinuation, return to fertility can be delayed. In some cases, it may be used to regulate menstrual cycles and improve fertility in estrogen-deficient states. |
| No specific food interactions reported. Grapefruit juice may moderately increase estradiol levels due to CYP3A4 inhibition; avoid excessive consumption. |
| Clinical Pearls | ESTROGEL (estradiol topical gel) provides systemic estrogen therapy for menopausal hormone therapy. Apply to clean, dry, intact skin on the upper arm, shoulder, or inner thigh. Rotate application sites and allow gel to dry for 5 minutes before covering with clothing. Avoid application to breasts, face, or irritated skin. Do not use with cream/sunscreen at the same site. Avoid skin-to-skin contact with others, especially children, until gel is dry. Monitor for signs of thromboembolism, endometrial cancer, and breast cancer. |
| Patient Advice | Apply the gel at the same time each day to clean, dry skin. · Rotate application sites (upper arm, shoulder, or inner thigh) to reduce skin irritation. · Avoid applying to the breasts, face, or irritated skin. · Let the gel dry for 5 minutes before dressing; wash hands after application. · Avoid skin contact with others, especially children and pets, until the gel has dried. · Do not use sunscreen or other skin products at the same application site. · Report any unusual vaginal bleeding, chest pain, shortness of breath, or vision changes immediately. · Smoking increases the risk of serious cardiovascular side effects; avoid smoking. · This medication does not protect against sexually transmitted infections or pregnancy. |